Participation in a Research Registry for Immune Disorders

Learn more about:
Related Clinical Trial
Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome. Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP) Participation in a Research Registry for Immune Disorders Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Interleukin-2 Treatment for Wiskott-Aldrich Syndrome Gene Therapy for WAS Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS) Molecular and Clinical Studies of Primary Immunodeficiency Diseases A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

Brief Title

Participation in a Research Registry for Immune Disorders

Official Title

NIH Participation to USIDNET Registry

Brief Summary

      Background:

      - People with primary immune deficiency diseases (PIDD) have weak immune systems. This makes
      it hard for their bodies to fight infection. The Immune Deficiency Foundation has a network
      to collect data about people with PIDD. It is called the United States Immunodeficiency
      Network. It will help doctors and scientists better understand these disorders. The goal is
      to get medical data for everyone with these disorders in the U.S. and Canada. Data will be
      stored in a registry. Researchers can use it to study if these disorders are increasing. They
      can also learn how the disorders are diagnosed and treated.

      Objectives:

      - To collect data on people with primary immune deficiency disorders.

      Eligibility:

      - People who have a PIDD.

      Design:

        -  Data can be added with no record of personal identity.

        -  Data can be added with identity kept separate. This data will be linked to the registry
           by a code number.

        -  Data for the registry includes:

        -  Family history

        -  Disease treatment

        -  Disease characteristics

        -  Medical history

        -  Laboratory data
    

Detailed Description

      The purpose of this protocol is to provide a resource for clinical and laboratory research
      through enrollment of known immunodeficiency patients into a national registry, the US
      Immunodeficiency Network (USIDNET). The registry data will expand NIH s and the nation s
      knowledge base about immune deficiency disorders and genetic mutations that lead to these
      disorders. Additional registrants from NIH protocols will not only increase the understanding
      of the molecular basis of these disorders, but also will serve to document and track the
      incidence and progression of complications.

      Objectives and specific aims

      The purpose of this proposal is to create a mechanism for depositing NIH data into USIDNET.
      The patient Registry is designed to obtain longitudinal data on a large number of patients
      with primary immunodeficiency diseases, and genetic carriers of these defects in order to:

        -  Learn more about the phenotypic variations seen in a large number of individual patients
           with the same rare molecular diagnosis.

        -  Determine the natural history of these genetic disorders of immunity and establish
           genotype-phenotype correlations.

        -  Learn effects of various treatment protocols used in these patients over time, including
           unexpected side effects that may be unique to a particular diagnostic group.

        -  To evaluate quality of life using standard tools and correlate these with genotype and
           treatment history.

        -  To promote collaborative research amongst interested investigators by identifying a
           larger pool of potential research subjects than would be available at their own
           institutions

        -  To identify patients with a specific diagnosis for potential participation in
           multi-institutional clinical trials designed for diagnosis or therapy or their specific
           disease.
    


Study Type

Observational


Primary Outcome

Prevalence


Condition

Primary Immunodeficiencies


Study Arms / Comparison Groups

 immunodeficiency
Description:  Individual of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

1000

Start Date

September 30, 2013

Completion Date

January 8, 2025

Primary Completion Date

January 8, 2025

Eligibility Criteria

        -  INCLUSION CRITERIA

        Individuals of all ages, gender, and races with an immunodeficiency disorder from NIH
        studies will be accepted for registration. No healthy volunteers will be enrolled.

        EXCLUSION CRITERIA

        Individuals with immunodeficiency associated with HIV infection, chemotherapy or other
        immunosuppressive therapies will not be accepted for registration unless there is clear
        evidence that these individuals also have a genetically determined immunodeficiency disease
        as well. Adult individuals who do not give informed consent will also be excluded.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Elizabeth K Garabedian, R.N., (301) 435-2443, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01953016

Organization ID

130199

Secondary IDs

13-HG-0199

Responsible Party

Sponsor

Study Sponsor

National Human Genome Research Institute (NHGRI)

Collaborators

 National Institute of Allergy and Infectious Diseases (NIAID)

Study Sponsor

Elizabeth K Garabedian, R.N., Principal Investigator, National Human Genome Research Institute (NHGRI)


Verification Date

March 9, 2021